.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,743,777

« Back to Dashboard

Claims for Patent: 6,743,777

Title: Cyclic peptide antifungal agents and process for preparation thereof
Abstract:Provided are compounds of the formula (1): ##STR1## wherein R' is hydrogen, methyl or NH.sub.2 C(O)CH.sub.2 --; R" and R'" are independently methyl or hydrogen; R adn R.sup.y are independently hydroxy or hydrogen; R.sub.1 is hydroxy, hydrogen, or hydroxysulfonyloxy; R.sub.7 is hydroxy, hydrogen, hydroxysulfonyloxy or phosphonooxy; R.sub.2 is a novel acyl side chain. Also provided are novel formulations, methods of inhibiting fungal and parasitic activity, and a process for preparing dideoxy (R=H) forms of the compounds.
Inventor(s): Burkhardt; Frederick J. (Indianapolis, IN), Debono; Manuel (Indianapolis, IN), Nissen; Jeffrey S. (Indianapolis, IN), Turner, Jr.; William W. (Bloomington, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:10/087,088
Patent Claims: 1. A pharmaceutical formulation comprising a compound having the following formula: ##STR255##

and a pharmaceutically acceptable carrier.

2. A method for inhibiting parasitic activity comprising contacting a formulation of claim 1 with a parasite.

3. A method of inhibiting fungal activity comprising contacting a formulation of claim 1 with a fungus.

4. A method of inhibiting the growth of organisms responsible for opportunistic infections in immunosuppressed individuals comprising administering a formulation of claim 1 to said individual.

5. A method of inhibiting the growth of Pneumocystis carinii comprising contacting a formulation of claim 1 with Pneumocystis carinii.

6. A pharmaceutical formulation comprising a compound represented by the formula ##STR256##

wherein R is --O(CH.sub.2).sub.3 CH.sub.3, --O(CH.sub.2).sub.4 CH.sub.3, --O(CH.sub.2).sub.5 CH.sub.3, --O(CH.sub.2).sub.2 O(CH.sub.2).sub.3 CH.sub.3, or --O(CH.sub.2).sub.2 OC(CH.sub.3).sub.3 and a pharmaceutically acceptable carrier.

7. The formulation of claim 6, wherein R is --O(CH.sub.2).sub.4 CH.sub.3.

8. A method for inhibiting parasitic activity comprising contacting a formulation of claim 6 with a parasite.

9. The method of claim 8, wherein R is --O(CH.sub.2).sub.4 CH.sub.3.

10. A method of inhibiting fungal activity comprising contacting a formulation of claim 6 with a fungus.

11. The method of claim 10, wherein R is --O(CH.sub.2).sub.4 CH.sub.3.

12. A method of inhibiting the growth of organisms responsible for opportunistic infections in immunosuppressed individuals comprising administering a formulation of claim 6 to said individual.

13. The method of claim 12, wherein R is --O(CH.sub.2).sub.4 CH.sub.3.

14. A method of inhibiting the growth of Pneumocystis carinii comprising contacting a formulation of claim 6 with Pneumocystis carinii.

15. The method of claim 14, wherein R is --O(CH.sub.2).sub.4 CH.sub.3.

16. A pharmaceutical formulation comprising a compound represented by the formula ##STR257##

and a pharmaceutically acceptable carrier.

17. A pharmaceutical formulation comprising a pharmaceutically acceptable salt of the formulation according to claim 16.

18. A method for inhibiting parasitic activity comprising contacting a formulation of claim 16 with a parasite.

19. A method of inhibiting fungal activity comprising contacting a formulation of claim 16 with a fungus.

20. A method of inhibiting the growth of organisms responsible for opportunistic infections in immunosuppressed individuals comprising administering a formulation of claim 16 to said individual.

21. A method of inhibiting the growth of Pneumocystis carinii comprising contacting a formulation of claim 16 with Pneumocystis carinii.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc